<DOC>
	<DOCNO>NCT00557609</DOCNO>
	<brief_summary>This multi-center , single arm intend evaluate anti-tumor effect ARQ 197 patient microphthalmia transcription factor associate ( MiT ) tumor . MiT tumor include clear cell sarcoma , alveolar soft part sarcoma , translocation associate renal cell carcinoma .</brief_summary>
	<brief_title>Phase 2 Study Patients With MiT Tumors</brief_title>
	<detailed_description>This multi-center , single arm , two-stage phase 2 study ARQ 197 patient microphthalmia transcription factor associate ( MiT ) tumor . ARQ 197 novel small molecule drug design block activity c-Met , think play multiple key role human cancer , include cancer cell growth , survival , angiogenesis , invasion metastasis . The microphthalmia transcription factor tumor ( MiT tumor ) clear cell sarcoma ( CCS ) , alveolar soft part sarcoma ( ASPS ) , translocation associate renal cell carcinoma ( RCC ) . These soft tissue cancer characterize common transcriptional mechanism lead inexorable spread resistance know therapy . They tend strike adolescent young adult , invariably fatal resectable diagnosis . Several academic laboratory show genetic translocation tumor upregulate c-Met , tumor dependent upon activity . The study enroll adolescent ( age 13 old ) adult patient histologically cytologically confirm MiT malignant disease . Eligible patient receive ARQ 197 twice daily . Treatment continue progression disease , unacceptable toxicity , another discontinuation criterion meet . During study , tumor evaluation perform baseline , 8-week interval . To evaluate patient 's safety drug 's toxicity , physical examination , laboratory evaluation , vitals sign , adverse event assessment perform throughout study . Blood sample PK analysis collect first cycle treatment 10 patient age 20 young . Archival tissue specimens relevant laboratory result patient ' gene translocation/fusion status collect . Tumor biopsy may also collect ( optional ) patient 's consent . If patient agree tumor sample may collect use core needle biopsy . In addition , explore biological response tumor ARQ 197 treatment , FDG-PET scanning perform three time point : within 14 day prior treatment , Day 8 ( ± 2 day ) Cycle 1 two cycle treatment coincide tumor measurement .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sarcoma , Clear Cell</mesh_term>
	<mesh_term>Sarcoma , Alveolar Soft Part</mesh_term>
	<criteria>1 . Histologically cytologically confirm unresectable locally advanced metastatic alveolar soft part sarcoma , clear cell sarcoma , translocation associate renal cell carcinoma 2 . ≥13 year old 3 . Male female patient childproducing potential must agree use double barrier contraception , oral contraceptive avoidance pregnancy measure study 30 day last ARQ 197 dose 4 . Females childbearing potential must negative serum pregnancy test 1 . Central nervous system metastasis unless stable ≥ 3 month treatment patient neural symptom 2 . Pregnant lactate 3 . Significant gastrointestinal disorder ( ) , opinion Investigator , could interfere absorption ARQ 197 ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric small bowel resection ) 4 . Unable unwilling swallow ARQ 197 capsule twice daily 5 . Known human immunodeficiency virus ( HIV ) , Hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection 6 . Bradycardia baseline know history arrhythmia 7 . Received ARQ 197 previously</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Microphthalmia transcription ( MiT ) factor associate tumor</keyword>
	<keyword>Alveolar soft part sarcoma ( ASPS )</keyword>
	<keyword>Clear cell sarcoma ( CCS )</keyword>
	<keyword>Renal cell carcinoma ( RCC )</keyword>
</DOC>